Fluticrem

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluticrem

Property Description
Active Ingredient Fluticasone Propionate
Form Cream (Emulsion)
Pharmacological Class Corticosteroid / Glucocorticoid
Common Use Relief of inflammatory skin symptoms
Origin Synthetic fluorinated derivative

Fluticrem: What Type of Medicine is Fluticasone Propionate?

Fluticrem is a prescription-only medicine whose therapeutic efficacy is derived from its single active ingredient, Fluticasone Propionate. This substance is a potent corticosteroid, specifically a synthetic member of the glucocorticoid class. Fluticasone Propionate is a synthetic fluorinated derivative that mimics the body's natural hormones to regulate localized immune and inflammatory responses in the skin. Being categorized as a topical steroid defines its fundamental therapeutic identity, indicating its primary role in controlling inflammatory conditions that respond to potent anti-inflammatory agents.


Composition and Form: Understanding the Fluticasone Cream

Fluticrem is supplied as a cream preparation strictly intended for topical administration to the skin. This dosage form is designed as an emulsion, combining the active Fluticasone Propionate within an aqueous and lipid base. The cream base is a differentiating factor, as it is engineered to be readily absorbed and leave a less occlusive, less greasy feel than traditional ointment preparations. The stability and efficient skin delivery provided by this emulsion base are essential for its therapeutic performance.


General Purpose: Why is Fluticrem Used?

The general purpose of this medicine is to provide rapid and targeted relief from the visible and sensory symptoms of inflammatory skin conditions. The inherent anti-inflammatory effect and localized immunosuppression delivered by Fluticasone Propionate quickly act to interrupt the cellular cascade that causes irritation and swelling. This core pharmacological action is essential for controlling the underlying excessive tissue response, offering symptomatic relief from the persistent discomfort, swelling, redness, and itching associated with various dermatological issues. Fluticasone Propionate is highly effective in suppressing inflammation due to its high affinity for the glucocorticoid receptor.

What side effects are possible with Fluticrem?

Fluticrem: Possible Side Effects and Safety Information

Fluticrem (Fluticasone Propionate) is a potent topical corticosteroid, and its official safety profile is structured to communicate both localized, expected adverse reactions and rare, serious systemic effects that may result from drug absorption.

Safety data, as classified by regulatory authorities, group side effects into frequency and System Organ Class (SOC) categories. The most frequently observed effects involve Skin and Subcutaneous Tissue Disorders.

Classification Examples of Officially Documented Adverse Reactions
Common Pruritus (itching)
Uncommon Local burning sensation
Very Rare Systemic effects, secondary infection, allergic contact dermatitis

The most significant, though very rare, systemic risks are associated with the Endocrine Disorders SOC. These include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome, which are potential consequences of increased absorption. Ophthalmic issues, specifically cataracts and glaucoma, are also documented as rare adverse reactions.

Risk of serious systemic effects is explicitly linked to the duration and extent of use. Adverse reactions such as skin atrophy (thinning) and striae (stretch marks) are documented as being more likely with prolonged and intensive use. Applying the cream under occlusive dressings or over large surface areas increases the potential for systemic exposure. Regulatory documents specifically note that pediatric patients are at greater risk of systemic toxicity, including HPA axis suppression, due to their higher skin surface area to body mass ratio.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Fluticrem (fluticasone propionate) topical cream is based on the risk of systemic absorption following inappropriate use rather than acute toxicity from a single event. Acute overdose following topical application is considered highly unlikely by regulatory agencies.

Primary Overdose Concern: Chronic Systemic Exposure

Overdose Risk Factor Potential Clinical Outcome
Prolonged use of excessive quantities HPA Axis Suppression (Adrenal insufficiency)
Use over large surface areas or under occlusive dressings Hypercortisolism (Cushing's syndrome)
Paediatric use (due to increased surface area to body weight ratio) Increased susceptibility to systemic effects

Emergency Actions and When to Seek Help

The critical risk associated with overuse is the development of systemic effects, such as adrenal suppression or Cushing’s syndrome, due to the steroid being absorbed into the bloodstream over time.

Immediate medical attention should be sought if signs of these systemic conditions are observed or suspected, which may manifest as unexplained weight gain, fluid retention, or fatigue.

If chronic overdose is confirmed by medical testing, the required action is generally a gradual, medically supervised withdrawal of the topical corticosteroid to allow the body's natural hormone production (HPA axis) to recover.

Therapeutic Uses of Fluticrem

Fluticasone Propionate cream is a topical corticosteroid indicated for managing the inflammatory and pruritic manifestations of various skin disorders. This medication is used to help address inflammation and ease the associated itching, redness, dryness, and scaling.

Core Therapeutic Uses and Benefits

Fluticrem is commonly used in the management of chronic skin conditions characterized by periods of heightened symptoms, including Atopic Dermatitis (Eczema) and Psoriasis. Its use is relevant during phases when symptoms may intensify temporarily to address the symptoms related to inflammatory or irritative states, such as characteristic redness, thickening, and scaling of the skin. By easing these primary symptoms, the cream provides supportive symptomatic relief that helps reduce the overall symptom load during acute flare-ups.

The cream is considered relevant for managing moderate to severe symptomatic episodes across various age groups, including adults and children 3 months of age and older. Its anti-inflammatory effect is intended for use during phases when symptoms become more noticeable and supportive symptom management is appropriate. This provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.


Quick Fact: Relief for Pruritus & Inflammation
This cream is commonly used to help manage symptoms related to inflammatory or irritative states, such as the intense itching and visible swelling associated with symptoms that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Fluticrem?

This section describes the population eligibility and non-eligibility for Fluticrem (Fluticasone Propionate Cream) based strictly on official regulatory labeling.

Contraindications and Non-Eligible Populations

Fluticrem must not be used by individuals with a known hypersensitivity to the active ingredient, Fluticasone Propionate, or any other component in the cream. Use is also strictly contraindicated in patients presenting with certain facial dermatological conditions, including rosacea and perioral dermatitis, or acne vulgaris. The cream must also be avoided if untreated primary skin infections (viral, bacterial, fungal, or parasitic) are present at the application site, as well as skin manifestations of tuberculosis or syphilis.


Age and Physiological Restrictions

The medicine is approved for use in adults and pediatric patients aged 3 months of age and older. Safety and efficacy have not been established in infants younger than 3 months of age. Use during pregnancy and lactation is restricted and should only be considered if the expected benefit justifies the potential risk. Furthermore, the cream must not be applied to the breasts while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The systemic absorption of Fluticasone Propionate, the active component in Fluticrem, is generally low following application to the skin. However, the medicine's metabolic clearance in the liver is mediated by the Cytochrome P450 3A4 (CYP3A4) enzyme, which forms the basis of its officially documented pharmacokinetic interactions.

Co-administration of Fluticrem with medicines classified as potent CYP3A4 inhibitors may reduce the clearance of Fluticasone Propionate, resulting in a risk of increased systemic exposure. Due to this risk, co-administration with the potent inhibitor Ritonavir is officially not recommended unless the potential benefits clearly outweigh the danger of systemic corticosteroid effects. Caution is also advised when using other potent inhibitors, such as the azole antifungals Ketoconazole and Itraconazole.

This increase in systemic concentration is documented to carry a risk of adverse outcomes, including Adrenal Suppression (HPA axis suppression) and features of Cushing's Syndrome. Furthermore, the food product Grapefruit Juice is also documented as a CYP3A4 inhibitor, and its consumption may lead to the same increased systemic corticosteroid effects. The risks associated with increased systemic exposure are noted to be more clinically significant in populations with Liver Impairment and in Young Age / Pediatric Patients.

Mechanism of Action

Fluticrem's physiological action is derived from its single active ingredient, Fluticasone Propionate, which operates through the specific regulation of inflammatory processes at the cellular and molecular level, based on its high binding affinity for the receptor.

Glucocorticoid Receptor Agonism and Gene Control

The mechanism begins when the molecule acts as a high-affinity agonist for the intracellular Glucocorticoid Receptor ( GR), which then enters the nucleus to directly control gene expression. This activity results in a dual mechanistic outcome: it actively inhibits the genes responsible for generating pro-inflammatory signals (e.g., via NF-kappa B) while simultaneously activating the genes that produce anti-inflammatory proteins, such as Annexin A1.


Molecular Modulation of Inflammatory Mediators

This genomic action cascades into the widespread modulation of inflammatory pathways, most notably by hindering the production of pro-inflammatory mediators. This includes blocking the synthesis of cytokines and chemokines, and regulating the Arachidonic Acid cascade to decrease the formation of vasodilatory compounds like prostaglandins. This critical step results in the physiological consequence of decreased local cellular infiltration and vasoconstriction.


Mechanism Constraints and Effect Dynamics

The anti-inflammatory effects generated by this mechanism are achieved by the biological process of synthesizing new proteins, which inherently requires a period of time to complete. Consequently, the maximal inhibition of inflammatory gene expression is dependent on the duration of this gene-regulatory process, defining the characteristic onset dynamics of the drug's effect profile.

Dosage and Administration Information

How to Use Fluticrem

Fluticrem (Fluticasone Propionate 0.05% Cream) is a topical corticosteroid. Instructions for use include the route of administration, the quantity, the frequency, and the maximum duration of use.


Official Administration Guidelines

Category Instructions
Route of Administration Exclusively for topical use (applied to the skin). It must not be applied to the eyes, mouth, or internally.
Standard Dosing Apply a thin film of the cream to the affected skin area only. Application involves gently rubbing the cream in upon delivery.
Frequency and Timing The standard schedule is once daily or twice daily (e.g., every 12 hours) to the afflicted areas. Once the condition is controlled, the frequency should be gradually reduced to the lowest effective dose.
Duration of Course Continuous therapy is generally limited to a maximum of 4 weeks to achieve initial control. The need for continued treatment must be re-evaluated by a healthcare professional if no improvement is observed within 2 weeks of continuous use.

Special Procedural Conditions

There are specific constraints on the method of application. The treated area should not be covered with occlusive dressings, bandages, or wraps unless this is specifically instructed by a physician. In the pediatric population, the cream is not to be applied in the diaper area, as the diaper may act as an occlusive covering. Application should also be avoided on the face, groin, or armpits unless explicitly directed by a prescriber.

Age-Group Use Rules

Use of the cream is generally permitted in adults and in pediatric patients above a minimum threshold (for example, 3 months of age). The safety and efficacy for use in infants younger than this minimum age have not been established.

Recent Clinical Evidence

Fluticrem: Recent Clinical Evidence

This section provides an overview of the data from clinical studies and research investigations involving fluticasone propionate cream.

Biological Activity Research

Preclinical research has explored the drug's anticipated biological activity. Studies examined the drug's biological activity in laboratory settings, and research has examined its association with changes in pain and inflammation. This research provides context for the subsequent clinical trials.


Clinical Trials and Outcomes

Studies have explored the drug's effects across several research groups, focusing on whether the research intervention was associated with changes in symptom severity, typically measured using established patient-reported scales.

Single-Agent Trials

  • Initial Phase Trials: Early phase 1 and 2 trials focused on determining appropriate administration levels and preliminary safety, often in small groups of healthy volunteers or individuals with the condition.
  • Phase 3 Trials: Later phase 3 trials evaluated whether the drug was associated with various outcomes, including markers of disease progression and quality of life. Outcomes in these studies were often compared to a placebo or an existing treatment.

Maintenance Therapy Studies

Several randomized controlled studies examined the use of fluticasone propionate cream in maintenance therapy for conditions like atopic dermatitis. In pediatric patient groups whose disease was stabilized, the application of the cream twice weekly in addition to an emollient was evaluated against the use of emollient alone.


Adverse Event Monitoring

The studies reported certain safety outcomes, including common and serious adverse events. Study authors noted that the most frequently reported side effects involved the gastrointestinal tract and mild, transient headaches.

  • Systemic Monitoring: Systemic absorption was monitored, particularly in pediatric patients where large body surface areas were treated. Studies assessed the frequency of adverse events over the duration of participation.
  • Study Population Exclusions: Individuals with severe kidney issues were often excluded from the study populations due to potential risks identified in preclinical research.

Conclusion of Research Findings

Research has investigated this approach as a potential area of study for the condition. While initial findings were explored, it is not yet clear whether a clear beneficial effect was identified across all applications and patient groups. More research is needed to determine the overall role of this treatment approach.

Key Studies & References

  1. Fluticasone in mild to moderate atopic dermatitis relapse: A randomized controlled trial

Frequently Asked Questions (FAQ)

Common questions about Fluticrem (FAQ)


Q: How quickly should I expect to feel a difference after starting Fluticrem?

Fluticrem’s active ingredient works by controlling gene expression to produce anti-inflammatory proteins, as described in official documents. Because this mechanism involves a biological process of synthesizing new proteins, the maximum effect on inflammation depends on the time this regulatory process takes. Therefore, the effect is not instantaneous, and its onset is defined by the drug's effect dynamics.


Q: Does using Fluticrem for a long time change the skin?

Official safety data indicates that using the cream for prolonged and intensive periods may lead to changes in the skin. Specifically, adverse reactions such as skin atrophy (thinning) and striae (stretch marks) are documented as being more likely with extended use. This risk is also higher when the cream is applied over large surface areas.


Q: Is it normal for my condition to come back after stopping Fluticrem?

Official information notes a potential for a steroid withdrawal reaction if the medicine is used over prolonged periods and then stopped without guidance. This reaction may involve the return of symptoms or new symptoms, such as skin redness and a burning sensation, appearing days or weeks after cessation. Gradual reduction in use is sometimes advised for long-term users.


Q: Can using too much Fluticrem cause internal side effects?

Yes, official warnings indicate that applying the cream over large surface areas or under occlusive dressings, especially for prolonged periods, increases the systemic absorption of the medicine. This heightened systemic exposure carries a risk of effects on the body's internal systems, including Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and features of Cushing's syndrome.


Q: Why do official documents advise caution when using Fluticrem under occlusive dressings?

Official warnings about occlusive dressings exist because covering the treated area enhances the penetration of the medicine through the skin, leading to a risk of increased systemic exposure. The increased systemic exposure can cause serious adverse effects. The warning exists because of this risk, and use of occlusive dressings is generally not recommended unless explicitly advised by a prescriber.


Q: Is Fluticrem safe to use during pregnancy?

Regulatory documents state that use during pregnancy is restricted and should only be considered if the expected benefit to the patient justifies the potential risk to the fetus. A healthcare professional must consider the risks and benefits, as adequate studies in pregnant women have not established a definitive risk profile.


Q: Is Fluticrem the same type of cream as hydrocortisone?

No, Fluticrem’s active ingredient is fluticasone propionate, which is officially classified as a potent topical corticosteroid. Hydrocortisone, by contrast, is generally classified as a low-potency topical corticosteroid. This difference in official classification reflects a difference in the medicine’s potency.


Q: Is Fluticrem used for conditions other than eczema?

Yes. Fluticrem is approved for relieving inflammatory and pruritic symptoms of corticosteroid-responsive dermatoses. This category includes conditions beyond eczema (atopic dermatitis), such as psoriasis and certain forms of contact dermatitis, as indicated by various regulatory sources.


Q: What if I forget to apply Fluticrem once?

Official guidance advises that if a dose is forgotten, it should be applied as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the next dose should be applied at the usual time. Official guidance advises against applying a double dose to make up for a forgotten one.


Q: Can Fluticrem be used while using other topical creams for moisture?

Official administration instructions advise that Fluticrem should not be used at the same time as other topical creams, such as emollients or moisturizers. Official instructions advise a waiting period, such as around 30 minutes, between applying Fluticrem and using other skin products.


Q: Are there any common foods or supplements that interact with Fluticrem?

Official documentation specifically notes that Grapefruit Juice is a substance that may interact with the medicine. Because grapefruit juice is a CYP3A4 inhibitor, consumption may potentially lead to increased systemic concentration of Fluticasone Propionate. There is no official information confirming the safety of using other specific common foods or supplements.


Q: Does Fluticrem make the skin more sensitive to sunlight?

Official regulatory adverse reaction lists for the medicine do not commonly list photosensitivity (increased sensitivity to sunlight) as a reported side effect. The most common skin-related effects documented are localized reactions like itching and a burning sensation.


Q: Can Fluticrem be applied to large areas of the body?

Official documentation advises caution when using the medicine on large areas of the body because this practice may increase the absorption of the product, leading to a greater risk of systemic toxicity, particularly in pediatric patients.


Q: Is Fluticrem suitable for sensitive skin types?

Official information notes that Fluticrem contains excipients (non-active ingredients) which may cause local skin reactions, such as contact dermatitis, in susceptible individuals. The presence of these components means this risk is noted in relation to patients with sensitive skin.


Q: How is the effectiveness of Fluticrem measured in clinical trials?

Clinical trials often measure the effectiveness of Fluticrem using standardized, validated tools to assess changes in the severity of the skin condition. Common measurements include established patient-reported scales or by evaluating the probability or incidence of a relapse during maintenance therapy studies.


Q: Can Fluticrem be used on broken skin?

Regulatory documents advise that the cream must be avoided if untreated primary skin infections are present at the application site. Since compromised skin integrity can increase absorption, and the presence of infection is a contraindication, the presence of infection at the site of application is a contraindication, and compromised skin may increase absorption.


Q: Does the application of Fluticrem cause rebound flare-ups?

The potential for a steroid withdrawal reaction is documented in official sources, particularly with prolonged use. This reaction, which can resemble a rebound flare-up, is associated with the sudden cessation of the medicine and can result in symptoms such as skin redness and a burning sensation.


Q: Is it possible to develop an allergy to Fluticrem itself?

Yes. Official documents state that the cream is contraindicated for those with a known hypersensitivity to any component. Furthermore, allergic contact dermatitis is listed as a very rare potential adverse effect, which may be suspected if a skin condition does not improve or appears to worsen.


Q: What official warnings exist about stopping Fluticrem suddenly?

Official information states that a healthcare provider should be consulted before suddenly stopping treatment, especially after long-duration use. The dose may be gradually reduced to prevent the potential for a steroid withdrawal reaction, where symptoms of the original condition may rapidly return or worsen.


Q: What are the key points to remember about Fluticrem's safety classification?

Official safety documents emphasize that Fluticrem is a potent topical corticosteroid. Key points of caution include the risk of HPA axis suppression with prolonged, high-dose, or occluded use; the increased susceptibility of pediatric patients to systemic toxicity; and the potential for local adverse reactions like skin atrophy.


Q: Is there any research on the long-term effects of Fluticrem on children's growth?

Regulatory information and supporting studies caution that due to the increased risk of systemic toxicity in children, the potential for effects on the Hypothalamic-Pituitary-Adrenal (HPA) axis is assessed during pediatric studies. Systemic absorption in children carries a risk of effects on the HPA axis, including a potential for growth retardation.


Q: What types of skin reactions are considered severe side effects of Fluticrem?

Officially documented, though very rare, local adverse reactions of concern include severe outcomes associated with prolonged use, such as skin atrophy (thinning) and the development of striae (stretch marks). The development of an allergic contact dermatitis is also considered a very rare local adverse effect.


Q: Is the main ingredient in Fluticrem commonly found in other medicine classes?

Yes. The active ingredient, fluticasone propionate, is a steroid commonly found in preparations used for other applications. For example, it is used in medicine classes for asthma (inhalers) and rhinitis/allergies (nasal sprays or drops), where it acts as a topical anti-inflammatory agent.


Q: Does Fluticrem help with conditions like contact dermatitis?

Yes, Fluticrem is indicated for the treatment of corticosteroid-responsive dermatoses. Official patient information sources explicitly list contact dermatitis as one of the inflammatory skin conditions for which the medicine is used.

How should Fluticrem be stored and disposed of?

How to Store and Dispose of Fluticrem (Fluticasone Propionate Cream)

Fluticrem must be stored under specific conditions to maintain its effectiveness. Regulatory documents mandate storage at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). It is essential to not freeze the cream and to protect it from excessive heat and moisture. The container must be kept tightly closed and stored out of the sight and reach of children.

Regarding stability, some official labeling advises to discard the product 6 months after first opening the tube. Unused or expired Fluticrem must be disposed of in accordance with local regulations, utilizing drug take-back programs when available. The cream must not be disposed of in wastewater or household trash if a proper disposal program exists.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluticrem found in:

A-Z Index: